Results 151 to 153 of about 34,375 (153)

HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas. [PDF]

ESMO Open
Filippini DM, Cabarrou B, Dupain C, Halladjian M, Coquan E, Sablin MP, Mazzarella L, Francisco M, Servant N, Tonini MM, Hundt AF, Castel-Ajgal Z, You B, Bigot F, Ghiringhelli F, Vansteene D, Gomez-Roca C, Cousin S, Lambert A, Saada-Bouzid E, Durando X, Abdeddaim C, Borel C, Chaltiel R, Borcoman E, Legrand F, Bernhart S, Jimenez M, Bièche I, Filleron T, Le Tourneau C, Kamal M, Jeannot E.   +32 more
europepmc   +1 more source

Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE. [PDF]

ESMO Open
Fayette J, Cropet C, Toullec C, Burgy M, Bruyas A, Sire C, Lagrange A, Clatot F, Vinches M, Iacob M, Martin L, Kaminsky MC, Vansteene D, Salas S, Champagnac A, Saintigny P, Gautier J, Pérol D, Bourhis J.   +18 more
europepmc   +1 more source

Venous Thromboembolism in Women with Breast and Gynaecological Cancers: What Do We Know and What Should We Do? [PDF]

Clin Appl Thromb Hemost
Poenou G, Corbaux P, Accassat S, Chauleur C, Bertoletti L.   +4 more
europepmc   +1 more source